Gossamer Bio Q3 2022 net loss $59.4M; cash $304.4M; TORREY topline expected Nov/Dec

Gossamer Bio, Inc.

2022-Q3 EPS reported -$2.14

Net loss $59.4M ($0.65/shr) vs $60.2M ($0.80/shr) in Q3 2021; cash $304.4M sufficient into Q2 2024.
R&D expenses $44.5M, G&A $11.5M for quarter ended Sep 30, 2022.
Phase 2 TORREY topline data for seralutinib expected in second half of Nov or first half of Dec 2022.
Enrollment ongoing in Phase 1b/2 STAR CNS study of GB5121 for relapsed/refractory CNS lymphomas.
Preclinical pipeline updates presented at multiple medical conferences; three internally developed programs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Gossamer Bio, Inc. reported third quarter ended September 30, 2022 results: net income Net loss for the quarter ended September 30, 2022, was $59.4 million, or $0.65 per share, EPS $0.65 per share.

Period: third quarter ended September 30, 2022
Net income: Net loss for the quarter ended September 30, 2022, was $59.4 million, or $0.65 per share
EPS: $0.65 per share
Result: reported results

Exact text from the filing

Gossamer Bio, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended September 30, 2022.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Gossamer Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001728117-22-000099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.